Testing effectiveness (Phase 2)Study completedNCT00494585What this trial is testingCEP-701 for PH-negative MyelofibrosisWho this might be right forLeukemiaMyelofibrosis M.D. Anderson Cancer Center 27
Testing effectiveness (Phase 2)Study completedNCT03136185What this trial is testingBomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)Who this might be right forMyelofibrosisPost-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)+1 more Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) 90
Large-scale testing (Phase 3)Not Yet RecruitingNCT07357727What this trial is testingPelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)Who this might be right forPrimary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF) Novartis Pharmaceuticals 460
Testing effectiveness (Phase 2)Study completedNCT00569660What this trial is testingPh II Study of Azacitidine in MyelofibrosisWho this might be right forMyelofibrosis M.D. Anderson Cancer Center 34
Post-approval studies (Phase 4)Active Not RecruitingNCT02386800What this trial is testingCINC424A2X01B Rollover ProtocolWho this might be right forPrimary MyelofibrosisPolycythemia VeraGraft Versus Host Disease+2 more Novartis Pharmaceuticals 279
Early research (Phase 1)Study completedNCT03895112What this trial is testingMPN-RC 118 AVID200 in MyelofibrosisWho this might be right forPrimary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis+2 more John Mascarenhas 21
Large-scale testing (Phase 3)Ended earlyNCT04551053What this trial is testingTo Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)Who this might be right forMyelofibrosisPrimary MyelofibrosisPost Essential Thrombocythemia Myelofibrosis+1 more Incyte Corporation 177
Large-scale testing (Phase 3)Study completedNCT03952039What this trial is testingAn Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibWho this might be right forPrimary MyelofibrosisPost-Polycythemia VeraMyelofibrosis Celgene 202
Testing effectiveness (Phase 2)WithdrawnNCT04629651What this trial is testingCaptopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative NeoplasmsWho this might be right forBone Marrow FibrosisMyeloproliferative Neoplasm Case Comprehensive Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT02226172What this trial is testingSingle-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With RuxolitinibWho this might be right forPrimary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis Pfizer 21
Testing effectiveness (Phase 2)Study completedNCT01423851What this trial is testingSafety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MFWho this might be right forPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis NS Pharma, Inc. 77
Testing effectiveness (Phase 2)Looking for participantsNCT05320198What this trial is testingStudy of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaWho this might be right forMyelofibrosis; AnemiaAnemiaMyelofibrosis+4 more Disc Medicine, Inc 150
Testing effectiveness (Phase 2)Study completedNCT02966353What this trial is testingEfficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.Who this might be right forPrimary MyelofibrosisPost-Polycythemia Vera-MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis Novartis Pharmaceuticals 51
Testing effectiveness (Phase 2)Looking for participantsNCT06770842What this trial is testingRopeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisWho this might be right forPrimary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Post Essential Thrombocythaemia Myelofibrosis (PET-MF) The University of Hong Kong 20
Testing effectiveness (Phase 2)Looking for participantsNCT05835466What this trial is testingReparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)Who this might be right forMyelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF) Icahn School of Medicine at Mount Sinai 26
Testing effectiveness (Phase 2)UnknownNCT01298934What this trial is testingLBH589 (Panobinostat) for the Treatment of MyelofibrosisWho this might be right forPrimary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related Myelofibrosis Ronald Hoffman 22
Testing effectiveness (Phase 2)Ended earlyNCT02587598What this trial is testingStudy of INCB053914 in Subjects With Advanced MalignanciesWho this might be right forSolid Tumors Incyte Corporation 97
Early research (Phase 1)Study completedNCT00910728What this trial is testingStudy to Assess the Safety of AZD1480 in Patients With Myeloproliferative DiseasesWho this might be right forPrimary Myelofibrosis (PMF)Post-Polycythaemia VeraEssential Thrombocythaemia Myelofibrosis AstraZeneca 65
Testing effectiveness (Phase 2)Study completedNCT01644110What this trial is testingRuxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MFWho this might be right forPrimary MyelofibrosisSecondary MyelofibrosisPMF+3 more University of Ulm 96
Testing effectiveness (Phase 2)UnknownNCT04878003What this trial is testingStudy of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisWho this might be right forPrimary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF) Kartos Therapeutics, Inc. 52